Drawing for NAKVAE

USPTO serial 79238102

NAKVAE

Reviewed by CopyMark Law Group

Reg. 5640102Status 404
Filing date
Status date
Registration date
Jan 1, 2019
Examiner
VO, JULIE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NAKVAE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 12, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Dec 20, 2022GPNXNOTIFICATION PROCESSED BY IB—
Apr 19, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Apr 19, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Apr 12, 2019GPNXNOTIFICATION PROCESSED BY IB—
Feb 8, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 8, 2019FIMPFINAL DISPOSITION PROCESSED—
Jan 31, 2019GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Jan 1, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 9, 2018GPNXNOTIFICATION PROCESSED BY IB—
Oct 16, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 26, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 26, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 26, 2018NPUBNOTICE OF PUBLICATION—
Sep 7, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 30, 2018DOCKASSIGNED TO EXAMINER—
Aug 14, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 3, 2018LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Aug 2, 2018SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance